The Full Wiki

More info on 3,4-Diaminopyridine

3,4-Diaminopyridine: Wikis

Advertisements

Note: Many of our articles have direct quotes from sources you can cite, within the Wikipedia article! This article doesn't yet, but we're working on it! See more info or our list of citable articles.

Encyclopedia

From Wikipedia, the free encyclopedia

3,4-Diaminopyridine
Systematic (IUPAC) name
3,4-Diaminopyridine
Identifiers
CAS number 54-96-6
ATC code  ?
PubChem 5918
ChemSpider 5705
Chemical data
Formula C 5H7N3  
Mol. mass 109.13
SMILES eMolecules & PubChem
Pharmacokinetic data
Bioavailability 30% [1],[2]
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.  ?
Legal status Phase III
Routes Oral

3,4-Diaminopyridine is an organic compound with the formula C5H3N(NH2)2. It is formally derived from pyridine by substitution of the 3 and 4 positions with an amino group.

Applications

3,4-Diaminopyridine experimental drug for the treatment of Lambert-Eaton Syndrome. In Lambert-Eaton Syndrome, acetylcholine release is inhibited as antibodies meant to target characteristic cancers target Ca2+ channels on the prejunctional membrane instead. 3,4-Diaminopyridine works by blocking potassium channel efflux in nerve terminals so that action potential duration is increased. Ca2+ channels can then be open for longer time and allow greater acetylcholine release to stimulate muscle at end plate. It is also used to treat many of the Congenital Myasthenic Syndromes.

This compound has also been proposed for the treatment of multiple sclerosis.[3]

See also

References

  1. ^ AAEM Quality Assurance Committee. American Association of Electrodiagnostic Medicine. (2001). "Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthena gravis or Lambert-Eaton myasthenic syndrome: summary statement". Muscle Nerve 24: 1236–1238. doi:10.1002/mus.1139.  
  2. ^ Lundh H, Nilsson O, Rosen I, Johansson S. (1993). "Practical aspects of 3,4-diaminopyridine treatment of the Lambert-Eaton myasthenic syndrome.". Acta Neurol Scand 88: 136–140.  
  3. ^ Judge S, Bever C (2006). "Potassium channel blockers in multiple sclerosis: neuronal Kv channels and effects of symptomatic treatment". Pharmacol. Ther. 111 (1): 224–59. doi:10.1016/j.pharmthera.2005.10.006. PMID 16472864.  
Advertisements

Advertisements






Got something to say? Make a comment.
Your name
Your email address
Message